文章预览
Tolebrutinib指引 Q： Thank you just on tolebrutinib just update
on timing and then really what the most likely base case expectations should be
I guess if I could distill it down to a single question. Do you think
tolebrutinib will be approvable in some form or another based on the upcoming
readouts or could it be a total zero? Thank you. A： Tim, thank you for the question. No update
on the timings as we discussed late August early September this year consistent
with what we've said. I'm mindful of course of our reporting obligations and we
will be deeply conscious of how we provide the data flow at the top of mind
just in terms of speculating on the outcomes of the trials of course I can't do
that but I have to say we're optimistic about the path for those drugs and I
would really point out simply that currently in multiple sclerosis there's huge
unmet medical need and secondary a progress disease and phase 2, we had really
interesting results so going forward we'll see the resul
………………………………
